Novo Nordisk's Dual Ledger: A Pediatric Insulin Nod, a CagriSema Footnote and Lilly's 39% Gauntlet

Novo Nordisk has picked up a fresh US regulatory green light, but the Danish drugmaker's pipeline wins are arriving against a backdrop of accelerating rival momentum — a split screen that puts the looming nine-month report squarely in the spotlight. Clinical milestones matter to shareholders, yet they are no substitute for hard numbers on how the business is actually performing.

Shares added 2.7% on Friday. The advance coincided with a positive corporate development, though no direct link between the two has been confirmed, so the move cannot be pinned cleanly on the regulatory news.

A weekly basal insulin for younger patients

On 23 October, Novo Nordisk disclosed FDA approval of Awiqli for children aged ten and older with type 2 diabetes, making it the first once-weekly insulin cleared for this patient group. The practical effect is a sharp cut in injection burden — from seven basal insulin shots a week down to a single dose — which touches daily routine directly.

Scope matters when sizing the news. The decision covers that specific age band and form of diabetes. It is a concrete regulatory step forward, but on its own it does not yet evidence additional revenue or a defined contribution to earnings.

A separate read-across came roughly two weeks ago, when Novo Nordisk published a post-hoc analysis of the REDEFINE 1 trial. Among 2,309 women with obesity or excess weight, the company reported average weight loss of 25.0% at 68 weeks under CagriSema, on the assumption that treatment was maintained. That caveat belongs to the finding, and so does the analysis's character: it supplements the trial evidence rather than representing a regulatory decision.

Lilly raises the commercial bar

Meanwhile, Eli Lilly is turning up the heat. On Thursday the US rival posted 39% revenue growth for the third quarter of 2026 and lifted its full-year sales guidance. Reuters framed the results as a sign of Lilly's widening edge over Novo Nordisk in the GLP-1 market — setting concrete growth figures from a competitor against Novo's own medical progress.

Lilly added to the picture on Wednesday, reporting positive topline Phase 3 data for retatrutide versus Ozempic in adults with type 2 diabetes. That study and its announcement are Lilly's, not a Novo Nordisk result.

Congress calendar adds another layer

The scientific diary is filling up as well. Novo Nordisk plans to present from its obesity portfolio at ObesityWeek in Washington from 14 to 17 November, including CagriSema analyses and insights into real-world use of the Wegovy pill. Twelve abstracts on semaglutid and the investigational efruxifermin are slated for the AASLD Liver Meeting in Denver from 5 to 9 November.

The value to investors lies not in the volume of presentations but in their findings and the limits of what they show. An announcement confirms a scheduled presentation — not an additional treatment success.

The 4 November anchor

Novo Nordisk is due to publish results for the first nine months of 2026 on 4 November, the next occasion to weigh regulatory progress and commercial performance side by side. That leaves three distinct valuation layers running in parallel: approved applications, supplementary efficacy analyses and data still to come. Keeping them apart is the surest way to avoid booking scientific progress prematurely as business success — and the share price gain alone does not settle the question.